CD34-based enrichment of genetically engineered human T cells for clinical use results in dramatically enhanced tumor targeting

Cancer Immunology, Immunotherapy

Volumn 59, Issue 6, 2010, Pages 851-862

  Norell, Håkan ^a   Zhang, Yi ^a   McCracken, James ^b   Martins Da Palma, Telma ^a   Lesher, Aaron ^a   Liu, Yueying ^a   Roszkowski, Jeffrey J ^b   Temple, Anquanette ^a   Callender, Glenda G ^b   Clay, Timothy ^c   Orentas, Rimas ^d   Guevara Patiño, José ^b   Nishimura, Michael I ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

^c DUKE UNIVERSITY   (United States)

^d Lentigen Corporation   (United States)

Author keywords

Immunotherapy; Melanoma; Selection; TCR; Transduction

Indexed keywords

CD34 ANTIGEN; MESSENGER RNA; RETROVIRUS VECTOR; T LYMPHOCYTE RECEPTOR; CANCER VACCINE; HYBRID PROTEIN;

ADOPTIVE TRANSFER; ANTINEOPLASTIC ACTIVITY; ARTICLE; CD34 SELECTION; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL ISOLATION; CELL POPULATION; CELL STRAIN HEPG2; CONTROLLED STUDY; EFFECTOR CELL; ENRICHMENT CULTURE; EX VIVO STUDY; FEASIBILITY STUDY; GENE EXPRESSION REGULATION; GENETIC ENGINEERING; GENETIC TRANSCRIPTION; GENETIC TRANSDUCTION; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; IMMUNOREACTIVITY; IN VIVO STUDY; MELANOMA CELL; MOLECULAR RECOGNITION; PRIORITY JOURNAL; TRANSGENE; ADOPTIVE IMMUNOTHERAPY; GENE DELETION; GENETICS; IMMUNOLOGY; IMMUNOMAGNETIC SEPARATION; MELANOMA; METABOLISM; PATHOLOGY; RETROVIRUS; T LYMPHOCYTE RECEPTOR GENE; TRANSPLANTATION;

ANTIGENS, CD34; CANCER VACCINES; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; GENES, T-CELL RECEPTOR; GENETIC ENGINEERING; HUMANS; IMMUNOMAGNETIC SEPARATION; IMMUNOTHERAPY, ADOPTIVE; MELANOMA; RECOMBINANT FUSION PROTEINS; RETROVIRIDAE; SEQUENCE DELETION; TRANSDUCTION, GENETIC;

EID: 77953090516     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-009-0810-8     Document Type: Article

References (45)

1. ME Dudley JC Yang R Sherry MS Hughes R Royal U Kammula PF Robbins J Huang DE Citrin SF Leitman J Wunderlich NP Restifo A Thomasian SG Downey FO Smith J Klapper K Morton C Laurencot DE White SA Rosenberg 2008 Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens J Clin Oncol 26 5233 5239 10.1200/JCO.2008.16.5449 1:CAS:528:DC%2BD1cXhsVyqsrbO 18809613
2. SA Rosenberg NP Restifo JC Yang RA Morgan ME Dudley 2008 Adoptive cell transfer: A clinical path to effective cancer immunotherapy Nat Rev 8 299 308 1:CAS:528:DC%2BD1cXjsFCmsLg%3D
3. SA Rosenberg ME Dudley 2009 Adoptive cell therapy for the treatment of patients with metastatic melanoma Curr Opin Immunol 21 233 240 10.1016/j.coi.2009.03.002 1:CAS:528:DC%2BD1MXlsVCgtb8%3D 19304471
4. TM Clay MC Custer J Sachs P Hwu SA Rosenberg MI Nishimura 1999 Efficient transfer of a tumor antigen-reactive TCR to human peripheral blood lymphocytes confers anti-tumor reactivity J Immunol 163 507 513 1:CAS:528:DyaK1MXktF2rsbk%3D 10384155
5. RJ Orentas SJ Roskopf GP Nolan MI Nishimura 2001 Retroviral transduction of a T cell receptor specific for an Epstein-Barr virus-encoded peptide Clin Immunol (Orlando, Fla) 98 220 228 10.1006/clim.2000.4977 1:CAS:528: DC%2BD3MXhvVartro%3D (Pubitemid 32150610)
6. JJ Roszkowski GE Lyons WM Kast C Yee K Van Besien MI Nishimura 2005 Simultaneous generation of CD8+ and CD4+ melanoma-reactive T cells by retroviral-mediated transfer of a single T-cell receptor Cancer Res 65 1570 1576 10.1158/0008-5472.CAN-04-2076 1:CAS:528:DC%2BD2MXhsFKqtbs%3D 15735047 (Pubitemid 40270187)
7. GG Callender HR Rosen JJ Roszkowski GE Lyons M Li T Moore N Brasic MD McKee MI Nishimura 2006 Identification of a hepatitis C virus-reactive T cell receptor that does not require CD8 for target cell recognition Hepatology 43 973 981 10.1002/hep.21157 1:CAS:528:DC%2BD28XkvFGmt7g%3D 16628627 (Pubitemid 43724622)
8. L Duval H Schmidt K Kaltoft K Fode JJ Jensen SM Sorensen MI Nishimura H von der Maase 2006 Adoptive transfer of allogeneic cytotoxic T lymphocytes equipped with a HLA-A2 restricted MART-1 T-cell receptor: A phase I trial in metastatic melanoma Clin Cancer Res 12 1229 1236 10.1158/1078-0432.CCR-05-1485 1:CAS:528:DC%2BD28XhsFaltLk%3D 16489078 (Pubitemid 43342513)
9. RA Morgan ME Dudley JR Wunderlich MS Hughes JC Yang RM Sherry RE Royal SL Topalian US Kammula NP Restifo Z Zheng A Nahvi CR de Vries LJ Rogers-Freezer SA Mavroukakis SA Rosenberg 2006 Cancer regression in patients after transfer of genetically engineered lymphocytes Science (New York, NY) 314 126 129 1:CAS:528:DC%2BD28XhtVCiurrK
10. LA Johnson RA Morgan ME Dudley L Cassard JC Yang MS Hughes US Kammula RE Royal RM Sherry JR Wunderlich CC Lee NP Restifo SL Schwarz AP Cogdill RJ Bishop H Kim CC Brewer SF Rudy C VanWaes JL Davis A Mathur RT Ripley DA Nathan CM Laurencot SA Rosenberg 2009 Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen Blood 114 535 546 10.1182/blood-2009-03-211714 1:CAS:528:DC%2BD1MXpt1Wmsb0%3D 19451549
11. JD Abad C Wrzensinski W Overwijk MA De Witte A Jorritsma C Hsu L Gattinoni CJ Cohen CM Paulos DC Palmer JB Haanen TN Schumacher SA Rosenberg NP Restifo RA Morgan 2008 T-cell receptor gene therapy of established tumors in a murine melanoma model J Immunother 31 1 6 10.1097/CJI.0b013e31815c193f 1:CAS:528:DC%2BD2sXhsVGgtL%2FF 18157006 (Pubitemid 351619398)
12. MA de Witte A Jorritsma A Kaiser MD van den Boom M Dokter GM Bendle JB Haanen TN Schumacher 2008 Requirements for effective antitumor responses of TCR transduced T cells J Immunol 181 5128 5136 18802117
13. DJ Schwartzentruber SS Hom R Dadmarz DE White JR Yannelli SM Steinberg SA Rosenberg SL Topalian 1994 In vitro predictors of therapeutic response in melanoma patients receiving tumor-infiltrating lymphocytes and interleukin-2 J Clin Oncol 12 1475 1483 1:STN:280:DyaK2c3ptlSktQ%3D%3D 8021739
14. SR Riddell M Elliott DA Lewinsohn MJ Gilbert L Wilson SA Manley SD Lupton RW Overell TC Reynolds L Corey PD Greenberg 1996 T-cell mediated rejection of gene-modified HIV-specific cytotoxic T lymphocytes in HIV-infected patients Nat Med 2 216 223 10.1038/nm0296-216 1:CAS:528:DyaK28Xps1yksg%3D%3D 8574968 (Pubitemid 26057556)
15. JC Morris M Conerly B Thomasson J Storek SR Riddell HP Kiem 2004 Induction of cytotoxic T-lymphocyte responses to enhanced green and yellow fluorescent proteins after myeloablative conditioning Blood 103 492 499 10.1182/blood-2003-07-2324 1:CAS:528:DC%2BD2cXmsFCjtg%3D%3D 14512305 (Pubitemid 38140079)
16. PF Robbins ME Dudley J Wunderlich M El-Gamil YF Li J Zhou J Huang DJ Powell Jr SA Rosenberg 2004 Cutting edge: Persistence of transferred lymphocyte clonotypes correlates with cancer regression in patients receiving cell transfer therapy J Immunol 173 7125 7130 1:CAS:528:DC%2BD2cXhtVCqur7N 15585832
17. AL Szymczak CJ Workman Y Wang KM Vignali S Dilioglou EF Vanin DA Vignali 2004 Correction of multi-gene deficiency in vivo using a single 'self-cleaving' 2A peptide-based retroviral vector Nat Biotechnol 22 589 594 10.1038/nbt957 1:CAS:528:DC%2BD2cXjsF2jsLw%3D 15064769 (Pubitemid 38585911)
18. JJ Roszkowski DC Yu MP Rubinstein MD McKee DJ Cole MI Nishimura 2003 CD8-independent tumor cell recognition is a property of the T cell receptor and not the T cell J Immunol 170 2582 2589 1:CAS:528:DC%2BD3sXht12htL4%3D 12594285
19. L Rivoltini KC Barracchini V Viggiano Y Kawakami A Smith A Mixon NP Restifo SL Topalian TB Simonis SA Rosenberg, et al. 1995 Quantitative correlation between HLA class I allele expression and recognition of melanoma cells by antigen-specific cytotoxic T lymphocytes Cancer Res 55 3149 3157 1:CAS:528:DyaK2MXmvVyitLs%3D 7541714
20. AA Neurauter M Bonyhadi E Lien L Nokleby E Ruud S Camacho T Aarvak 2007 Cell isolation and expansion using Dynabeads Adv Biochem Eng Biotechnol 106 41 73 1:CAS:528:DC%2BD1cXhslOgtLk%3D 17680228
21. J Zhou X Shen J Huang RJ Hodes SA Rosenberg PF Robbins 2005 Telomere length of transferred lymphocytes correlates with in vivo persistence and tumor regression in melanoma patients receiving cell transfer therapy J Immunol 175 7046 7052 1:CAS:528:DC%2BD2MXhtF2isr%2FM 16272366
22. X Shen J Zhou KS Hathcock P Robbins DJ Powell Jr SA Rosenberg RJ Hodes 2007 Persistence of tumor infiltrating lymphocytes in adoptive immunotherapy correlates with telomere length J Immunother 30 123 129 10.1097/01.cji. 0000211321.07654.b8 1:CAS:528:DC%2BD2sXjtVGi 17198091 (Pubitemid 46052211)
23. J Wang OW Press CG Lindgren P Greenberg S Riddell X Qian C Laugen A Raubitschek SJ Forman MC Jensen 2004 Cellular immunotherapy for follicular lymphoma using genetically modified CD20-specific CD8+ cytotoxic T lymphocytes Mol Ther 9 577 586 10.1016/j.ymthe.2003.12.011 1:CAS:528:DC%2BD2cXjtVChu7k%3D 15093188 (Pubitemid 38578808)
24. D Kabelitz O Janssen 1997 Antigen-induced death of T-lymphocytes Front Biosci 2 d61 d77 1:CAS:528:DyaK1cXhtVOitr8%3D 9159213
25. EA de Wynter D Ryder F Lanza G Nadali H Johnsen P Denning-Kendall B Thing-Mortensen F Silvestri NG Testa 1999 Multicentre European study comparing selection techniques for the isolation of CD34+ cells Bone Marrow Transplant 23 1191 1196 10.1038/sj.bmt.1701789 10382960
26. Y Jing LR Moore PS Williams JJ Chalmers SS Farag B Bolwell M Zborowski 2007 Blood progenitor cell separation from clinical leukapheresis product by magnetic nanoparticle binding and magnetophoresis Biotechnol Bioeng 96 1139 1154 10.1002/bit.21202 1:CAS:528:DC%2BD2sXkt1Cgt74%3D 17009321 (Pubitemid 46648674)
27. B Fehse A Richters K Putimtseva-Scharf H Klump Z Li W Ostertag AR Zander C Baum 2000 CD34 splice variant: An attractive marker for selection of gene-modified cells Mol Ther 1 448 456 10.1006/mthe.2000.0068 1:CAS:528:DC%2BD38XhvF2iu7o%3D 10933966
28. MP Rettig JK Ritchey TE Meyerrose JS Haug JF DiPersio 2003 Transduction and selection of human T cells with novel CD34/thymidine kinase chimeric suicide genes for the treatment of graft-versus-host disease Mol Ther 8 29 41 10.1016/S1525-0016(03)00142-4 1:CAS:528:DC%2BD3sXkvFGntb0%3D 12842426 (Pubitemid 36939294)
29. D Sangiolo M Lesnikova RA Nash MC Jensen A Nikitine HP Kiem GE Georges 2007 Lentiviral vector conferring resistance to mycophenolate mofetil and sensitivity to ganciclovir for in vivo T-cell selection Gene Ther 14 1549 1554 10.1038/sj.gt.3303018 1:CAS:528:DC%2BD2sXhtFKltbnP 17805303 (Pubitemid 47570715)
30. E Bennour C Ferrand JP Remy-Martin JM Certoux S Gorke W Qasim HB Gaspar T Baumert A Duperrier M Deschamps B Fehse P Tiberghien E Robinet 2008 Abnormal expression of only the CD34 part of a transgenic CD34/herpes simplex virus-thymidine kinase fusion protein is associated with ganciclovir resistance Hum Gene Ther 19 699 709 10.1089/hum.2007.060 1:CAS:528:DC%2BD1cXovFWmsbY%3D 18557699 (Pubitemid 352009909)
31. MH Heemskerk RS Hagedoorn MA van der Hoorn LT van der Veken M Hoogeboom MG Kester R Willemze JH Falkenburg 2007 Efficiency of T-cell receptor expression in dual-specific T cells is controlled by the intrinsic qualities of the TCR chains within the TCR-CD3 complex Blood 109 235 243 10.1182/blood-2006-03-013318 1:CAS:528:DC%2BD2sXivVyruro%3D 16968899 (Pubitemid 46053064)
32. KB Scholten D Kramer EW Kueter M Graf T Schoedl CJ Meijer MW Schreurs E Hooijberg 2006 Codon modification of T cell receptors allows enhanced functional expression in transgenic human T cells Clin Immunol (Orlando, Fla) 119 135 145 10.1016/j.clim.2005.12.009 1:CAS:528:DC%2BD28XjsFOgs78%3D
33. A Jorritsma R Gomez-Eerland M Dokter W van de Kasteele YM Zoet II Doxiadis N Rufer P Romero RA Morgan TN Schumacher JB Haanen 2007 Selecting highly affine and well-expressed TCRs for gene therapy of melanoma Blood 110 3564 3572 10.1182/blood-2007-02-075010 1:CAS:528:DC%2BD2sXhtlarur3E 17660381 (Pubitemid 350159623)
34. J Kuball ML Dossett M Wolfl WY Ho RH Voss C Fowler PD Greenberg 2007 Facilitating matched pairing and expression of TCR chains introduced into human T cells Blood 109 2331 2338 10.1182/blood-2006-05-023069 1:CAS:528: DC%2BD2sXnslygsrk%3D 17082316 (Pubitemid 46425872)
35. CJ Cohen Y Zhao Z Zheng SA Rosenberg RA Morgan 2006 Enhanced antitumor activity of murine-human hybrid T-cell receptor (TCR) in human lymphocytes is associated with improved pairing and TCR/CD3 stability Cancer Res 66 8878 8886 10.1158/0008-5472.CAN-06-1450 1:CAS:528:DC%2BD28XovF2ht7c%3D 16951205 (Pubitemid 44449206)
36. J Kuball B Hauptrock V Malina E Antunes RH Voss M Wolfl R Strong M Theobald PD Greenberg 2009 Increasing functional avidity of TCR-redirected T cells by removing defined N-glycosylation sites in the TCR constant domain J Exp Med 206 463 475 10.1084/jem.20082487 1:CAS:528:DC%2BD1MXit1Kju78%3D 19171765
37. ME Dudley J Wunderlich MI Nishimura D Yu JC Yang SL Topalian DJ Schwartzentruber P Hwu FM Marincola R Sherry SF Leitman SA Rosenberg 2001 Adoptive transfer of cloned melanoma-reactive T lymphocytes for the treatment of patients with metastatic melanoma J Immunother 24 363 373 10.1097/00002371- 200107000-00012 1:CAS:528:DC%2BD3MXntFGnt70%3D 11565838 (Pubitemid 32825868)
38. F Sallusto D Lenig R Forster M Lipp A Lanzavecchia 1999 Two subsets of memory T lymphocytes with distinct homing potentials and effector functions Nature 401 708 712 10.1038/44385 1:CAS:528:DyaK1MXntVWntrw%3D 10537110 (Pubitemid 29485217)
39. L Lefrancois AL Marzo 2006 The descent of memory T-cell subsets Nat Rev Immunol 6 618 623 10.1038/nri1866 1:CAS:528:DC%2BD28Xnt1yisLg%3D 16868553 (Pubitemid 44134095)
40. J Huang KW Kerstann M Ahmadzadeh YF Li M El-Gamil SA Rosenberg PF Robbins 2006 Modulation by IL-2 of CD70 and CD27 expression on CD8 + T cells: importance for the therapeutic effectiveness of cell transfer immunotherapy J Immunol 176 7726 7735 1:CAS:528:DC%2BD28Xlt1Cksb4%3D 16751420
41. KQ Tran J Zhou KH Durflinger MM Langhan TE Shelton JR Wunderlich PF Robbins SA Rosenberg ME Dudley 2008 Minimally cultured tumor-infiltrating lymphocytes display optimal characteristics for adoptive cell therapy J Immunother 31 742 751 10.1097/CJI.0b013e31818403d5 1:CAS:528:DC%2BD1cXhtFCrtLzJ 18779745
42. A Boni P Muranski L Cassard C Wrzesinski CM Paulos DC Palmer L Gattinoni CS Hinrichs CC Chan SA Rosenberg NP Restifo 2008 Adoptive transfer of allogeneic tumor-specific T cells mediates effective regression of large tumors across major histocompatibility barriers Blood 112 4746 4754 10.1182/blood-2008-07- 169797 1:CAS:528:DC%2BD1cXhsVCltbjK 18799724
43. CM Diaz-Montero S El Naggar A Al Khami R El Naggar AJ Montero DJ Cole ML Salem 2008 Priming of naive CD8+ T cells in the presence of IL-12 selectively enhances the survival of CD8+ CD62Lhi cells and results in superior anti-tumor activity in a tolerogenic murine model Cancer Immunol Immunother 57 563 572 10.1007/s00262-007-0394-0 1:CAS:528:DC%2BD1cXhtV2isrs%3D 17726606 (Pubitemid 351170539)
44. Y Zhao MR Parkhurst Z Zheng CJ Cohen JP Riley L Gattinoni NP Restifo SA Rosenberg RA Morgan 2007 Extrathymic generation of tumor-specific T cells from genetically engineered human hematopoietic stem cells via Notch signaling Cancer Res 67 2425 2429 10.1158/0008-5472.CAN-06-3977 1:CAS:528:DC%2BD2sXivV2gurk%3D 17363559 (Pubitemid 46548926)
45. S Newrzela K Cornils Z Li C Baum MH Brugman M Hartmann J Meyer S Hartmann ML Hansmann B Fehse D von Laer 2008 Resistance of mature T cells to oncogene transformation Blood 112 2278 2286 10.1182/blood-2007-12-128751 1:CAS:528:DC%2BD1cXhtFCrurnO 18566328